Neural mechanisms mediating the effects of expectation in visceral placebo analgesia: An fMRI study in healthy placebo responders and nonresponders


This functional magnetic resonance imaging study analysed the behavioural and neural responses during expectation-mediated placebo analgesia in a rectal pain model in healthy subjects. In N = 36 healthy subjects, the blood oxygen level–dependent (BOLD) response during cued anticipation and painful rectal stimulation was measured. Using a within-subject design, placebo analgesia was induced by changing expectations regarding the probability of receiving an analgesic drug to 0%, 50%, and 100%. Placebo responders were identified by median split based on pain reduction (0% to 100% conditions), and changes in neural activation correlating with pain reduction in the 0% and 100% conditions were assessed in a regions-of-interest analysis. Expectation of pain relief resulted in overall reductions in pain and urge to defecate, and this response was significantly more pronounced in responders. Within responders, pain reduction correlated with reduced activation of dorsolateral and ventrolateral prefrontal cortices, somatosensory cortex, and thalamus during cued anticipation (paired t tests on the contrast 0% > 100%); during painful stimulation, pain reduction correlated with reduced activation of the thalamus. Compared with nonresponders, responders demonstrated greater placebo-induced decreases in activation of dorsolateral prefrontal cortex during anticipation and in somatosensory cortex, posterior cingulate cortex, and thalamus during pain. In conclusion, the expectation of pain relief can substantially change perceived painfulness of visceral stimuli, which is associated with activity changes in the thalamus, prefrontal, and somatosensory cortices. Placebo analgesia constitutes a paradigm to elucidate psychological components of the pain response relevant to the pathophysiology and treatment of chronic abdominal pain.

Source:Pain.

 

 

 

 

The Antinociceptive Activity of Intrathecally Administered Amiloride and Its Interactions With Morphine and Clonidine in Rats


In this study, we aimed to evaluate the antinociceptive interaction between intrathecally administered amiloride and morphine or clonidine. Using rats chronically implanted with lumbar intrathecal catheters, we examined the ability of intrathecal amiloride, morphine, clonidine, and mixtures of amiloride-morphine and amiloride-clonidine to alter tail-flick latency. To characterize any interactions, isobolographic analysis was performed. The effects of pretreatment with intrathecally administered naloxone or yohimbine were tested. Intrathecal administration of amiloride (25–150 μg), morphine (.25–10 μg), or clonidine (.5–10 μg) alone produced significant dose-dependent antinociception in the tail-flick test. The median effective dose (ED50) values for intrathecally administered amiloride, morphine, and clonidine were 120.5 μg, 5.0 μg, and 4.4 μg, respectively. Isobolographic analysis exhibited a synergistic interaction after coadministration of amiloride-morphine and amiloride-clonidine. Intrathecal pretreatment with naloxone (10 μg) completely blocked the antinociceptive effects of morphine and the amiloride-morphine mixture. Intrathecal pretreatment with yohimbine (20 μg) completely blocked the antinociceptive effect of clonidine and antagonized the effect of the amiloride-clonidine mixture. There was no motor dysfunction or significant change in blood pressure or heart rate after the intrathecal administration of amiloride, amiloride-morphine, and amiloride-clonidine. The synergistic effect observed after the coadministration of amiloride and morphine or clonidine suggests a functional interaction among calcium channels, μ-receptors and α2-receptors at the spinal cord level of the nociceptive processing system.

Perspective

Although intrathecal morphine and clonidine produces pronounced analgesia, antinociceptive doses of intrathecal morphine and clonidine produce several side effects, including hypotension, bradycardia, sedation, and tolerance. This article presents antinociceptive synergistic interaction between amiloride and morphine, amiloride, and clonidine on thermal nociceptive tests in the rat.

Source:Journal of Pain.

 

Another new tool for the diagnostic bronchoscopist


Solitary pulmonary nodules (SPNs), defined as rounded lesions ❤ cm completely surrounded by an aerated lung, are increasingly identified by modern chest radiography and thoracic CT. As CT screening studies report and the debate over the place of national lung cancer screening programmes intensifies, the need for algorithms to efficiently investigate SPNs will become even more important.

Peripheral pulmonary lesions can be biopsied by various techniques. The most commonly used approach in the UK is transthoracic needle aspiration or core biopsy usually performed under CT guidance. The diagnostic sensitivity for malignancy exceeds 90% in experienced hands but up to 44% of biopsies in benign disease are non-diagnostic. While generally safe, it is not without complications; in a large UK-based survey, pneumothorax occurred in 20.5% of cases and intercostal tube drainage was required in 3%.

Flexible bronchoscopes can be used to approach peripheral lesions but the reported diagnostic sensitivity rates are considerably lower than for CT-guided needle biopsy. Sensitivity has been shown to be dependent upon the size of lesion, the distance from the hilum and the presence of a bronchus leading to the lesion on CT (the CT bronchus sign). A systematic review found that the diagnostic yield was 33% for lesions <2 cm in the outer third of the lung. Historically, the approach taken has been to use a thin bronchoscope and perform a combination of bronchial washings, brushings and transbronchial biopsy targeting the appropriate segmental or subsegmental bronchus sometimes with the assistance of fluoroscopy. More recently, several groups have reported their experience of using radial endobronchial ultrasound (EBUS) to guide biopsy of peripheral lesions. Radial EBUS provide 360° images of the airway wall and surrounding structures. Previously, this technique was often employed to identify the position of parabronchial or paratracheal lymph nodes prior to sequential (non-ultrasound guided) transbronchial needle aspiration (TBNA).4 However, this application has essentially been superseded by the development of linear EBUS. Nowadays, radial EBUS is predominantly used to localise a peripheral lesion and allow placement of a guide sheath through which biopsies can be taken. Diagnostic yields in the range of 58–80% have been reported. While radial EBUS helps with localisation of a peripheral lesion, the problem of navigating to the appropriate bronchus remains, which results in a long learning curve and lengthy procedures and has in large part been responsible for the low uptake of the technique in clinical practice. Therefore, in recent years considerable effort has been directed at the development of navigation systems to aid bronchoscope placement. Eberhardt et al showed that a combination of electromagnetic navigation and radial EBUS was superior to either technique alone. In Thorax, Ishida et al report a randomised trial that assessed the role of a virtual bronchoscopic navigation system to facilitate radial EBUS placement of a guide sheath prior to biopsy of peripheral pulmonary lesions. The diagnostic yield using the navigation system in combination with EBUS was 80%, significantly higher than in the control arm (67%), which used EBUS alone. The duration of the examination was shorter (24.0 vs 26.2 min, p=0.016), which is an important consideration in a procedure performed under sedation. The navigation system employed sophisticated computer reconstruction of virtual bronchoscopic images alongside standard video bronchoscopy. Although not widely available at this time, the approach used by Ishida and colleagues appears simpler and easier to use than some of the other commercially available navigation systems. However, at this time no head-to-head studies of the various navigation system approaches have been published.

The improvements in the diagnostic yield of bronchoscopic approaches increase the options available to clinicians investigating peripheral lesions. Increasingly, respiratory physicians are growing in confidence and experience with ultrasound. In the same way that linear EBUS-TBNA has been taken up by many bronchoscopists who previously lacked confidence to perform conventional TBNA, it is likely that improved navigation systems will encourage the spread of radial EBUS for biopsy of peripheral lesions. At present, however, experience in radial EBUS is limited to a relatively small number of specialist centres.

Faced with a choice of biopsy techniques, the question arises as to how best to approach a SPN. In considering this, a number of factors need to be taken into account. Clearly, accessibility to a technique and local expertise will play a significant role. At present, in the majority of centres percutaneous biopsy is more readily available and has a high sensitivity for malignancy. However, the risk of pneumothorax with transthoracic biopsy is considerably higher than that reported for endobronchial approaches and for patients in whom pneumothorax may cause significant clinical compromise, navigation-aided radial EBUS may be an appropriate first approach especially if there is CT evidence of an air bronchogram sign—an airway leading directly to the lesion.

In assessing a patient with suspected lung cancer, it is essential to consider the extent of disease and target biopsies appropriately. Although the updated NICE guidelines for the management of lung cancer (2011) omitted radial EBUS for lack of available evidence, one of the new recommendations is that clinicians should choose investigations that give the most information about diagnosis and staging with least risk to the patient.14 Not infrequently, patients undergo more than one biopsy procedure, first for diagnosis and then for staging, which are both arduous for the patient and costly to the NHS. For instance, in the past a patient may initially have had a transthoracic biopsy of a peripheral lesion before moving on to have mediastinal lymph node assessment by linear EBUS or mediastinoscopy. The new staging algorithms recommend that patients who may have disease suitable for treatment with curative intent should have enlarged mediastinal or other lesions biopsied in preference to the primary lesion. Identification of appropriate targets will come from the increasing use of PET-CT at an earlier time point in the staging algorithm to help direct biopsies. In the future, selected patients could have a single endobronchial procedure that comprises navigation-aided radial EBUS to biopsy a peripheral lesion combined with linear endobronchial and/or endoscopic ultrasound for mediastinal staging. Such an approach is already being undertaken, usually under general anaesthesia for patient comfort and tolerance, in a few highly specialised centres in continental Europe and the USA. However, further trials comparing the efficacy of endobronchial versus percutaneous biopsy strategies are required before firmer recommendations can be made.

As the diagnostic and staging algorithms for lung cancer evolve, it is essential that in parallel with developments in technology work is undertaken on quality of life and health resource use, an area that is frequently overlooked. The endobronchial approach to peripheral lesions is no exception and the approach documented by Ishida et al  joins the existing literature on electromagnetic navigation systems, ultrathin bronchoscopy and fluoroscopy-assisted bronchoscopy. Unfortunately, the current paper stopped short of incorporating an economic analysis, which was an opportunity missed.

The marked upturn in interest in thoracic oncology among respiratory physicians in recent years is partly stimulated by the growth in tools available to the bronchoscopist both for diagnosis and for therapy. Linear EBUS is gaining widespread acceptance and a number of centres are combining this procedure with endoscopic ultrasound. As navigation systems improve, it is likely that the use of radial EBUS will also spread. While continued equipment development is to be encouraged, it will be equally important to address training and ensure that operators achieve and maintain high levels of diagnostic accuracy. This may require regional centralisation of specialist services in order to be cost and manpower effective. At present, other than recommendations that cancer networks in England and Wales should have access to these specialist techniques,there is no strategic development plan with the result that interested clinicians and trusts are developing services on an ad hoc basis. In addition to training, the challenge over the next few years will be to ensure that there is a coordinated approach to the development of specialist bronchoscopy services to allow equity of access for the population as a whole.

Source:Thorax

Radiotherapy Matters for Locally Advanced Prostate Cancer


Adding radiotherapy to androgen-deprivation therapy improved overall and disease-specific survival.

Despite the ability of prostate cancer screening to identify patients with clinically organ-confined (T1c) prostate cancer, a troubling number of men still present with locally advanced — high-grade, high-stage, high–prostate-specific antigen (PSA) — disease. During the past 10 to 15 years, randomized trials have shown that optimal management of these patients requires a multimodality treatment, such as radiotherapy (RT) plus androgen-deprivation therapy (ADT) or radical prostatectomy plus adjuvant RT.

To further test the benefits of adding RT to ADT in men with locally advanced prostate cancer, international investigators conducted a randomized, phase III trial involving 1205 men with stage T3 or T4 (N0, NX, M0) disease or clinical T2 tumors with either a PSA concentration of >40 ng/mL or a PSA concentration >20 ng/mL and a Gleason score 8. Patients received lifelong ADT (bilateral orchiectomy or luteinizing-hormone–releasing hormone agonist) with or without RT (65–69 Gy to the prostate and seminal vesicles and 45 Gy to the pelvic nodes) given within 8 weeks of randomization.

During a median follow-up of 6.0 years, prostate cancer was the cause of death in 140 (44%) of the 320 patients who died; of these 140 deaths, 89 (51%) occurred in the ADT-only group, and 51 (35%) occurred in the ADT plus RT group. Severe (>grade 3) late adverse effects were uncommon among all patients. Overall survival (the primary endpoint) and disease-specific survival were improved by 8% and 10%, respectively, with RT plus ADT versus ADT alone. Approximately 10% of patients in the ADT-only group subsequently received salvage RT for local progression.

Comment: These results are important in that they validate the benefit of adding RT to ADT, but they do not change the standard of care. As the authors note, the finding that nearly 10% of patients in the ADT-only group received subsequent RT likely diminished the true benefit of RT. Although the study was well executed, the authors acknowledge its limitations, including the reliance on the local investigator to define cause of death. Moreover, the authors’ assertion that no clinically important adverse effects resulted from late-treatment toxicity was questioned by an editorialist who noted that the absence of significant long-term urinary or bowel effects challenges many published and clinical experiences.

Source: Journal Watch Oncology and Hematology.

Short-Course Combo Therapy for Latent TB Equivalent to Longer Monotherapy


A 3-month combination treatment regimen (isoniazid plus rifapentine) for latent tuberculosis is as effective as the standard 9-month isoniazid regimen, according to an international study in the New England Journal of Medicine.
Some 7700 patients with latent TB and at high risk for progression were recruited, primarily in the United States and Canada. They underwent randomization either to 9 months of self-administered daily isoniazid or to 3 months of combination therapy, administered weekly under direct supervision. By follow-up at 3 years, confirmed TB had developed in 0.2% of the combination-therapy group and 0.4% of those taking isoniazid only, showing that short-course combination therapy was noninferior to standard therapy. Patients taking combination therapy were more likely to discontinue treatment (5% vs. 4%).
Hepatotoxicity was more common in the isoniazid-only group, but hypersensitivity reactions were more common with combination therapy.
Source:NEJM

Comparison Induction Regimens for HIV-Associated Cryptococcal Meningitis of AmB-Based


In resource-limited settings where 5-FC is not available, high-dose fluconazole in combination with amphotericin B may be an alternative option for induction therapy.

Cryptococcal meningitis (CM) is one of the leading causes of AIDS-related mortality in sub-Saharan Africa. The currently recommended therapy for CM is amphotericin B (AmB) plus 5-flucytosine (5-FC); however, 5-FC is not available in many resource-limited settings. Fluconazole is an attractive alternative to 5-FC because it is inexpensive and widely available, but its relative efficacy is still under evaluation. Now, data from a small randomized trial suggest that the two drugs might be comparable.

Eighty antiretroviral-naive HIV-infected patients in South Africa with their first episode of CM were randomized to receive one of four induction treatment regimens: AmB plus 5-FC, AmB plus fluconazole (at 600 mg twice daily or 800 mg daily), or AmB plus voriconazole (only patients who were not on rifampin were allowed in this group). After 2 weeks of induction therapy, all patients received fluconazole at 400 mg daily for 8 weeks and 200 mg daily thereafter. Elevated intracranial pressure was managed with serial lumbar punctures. Antiretroviral therapy was initiated 2 or more weeks after the start of antifungal treatment.

All the induction regimens had similar early fungicidal activity. Overall mortality was 12% at week 2 and 29% at week 10, with no significant differences among treatment groups. AmB-related anemia and nephrotoxicity were common, causing 10% of patients to discontinue therapy before 2 weeks. Serious toxicities related to use of 5-FC or fluconazole were uncommon.

Comment: This important study shows that in combination with AmB, high-dose fluconazole has similar early fungicidal activity as 5-FC and yields comparable outcomes. The study’s main limitation is the small number of patients in each treatment group. A previous study found a trend toward improved early survival with high-dose fluconazole plus AmB compared with AmB alone , although the results were not definitive. A phase III trial comparing AmB alone, AmB plus 5-FC, and AmB plus high-dose fluconazole is being conducted in Vietnam, and the results are eagerly awaited. In the interim, the findings of the current study support upcoming WHO guidelines recommending high-dose fluconazole plus AmB as induction therapy in resource-limited settings where 5-FC is not available.

Source: Journal Watch HIV/AIDS Clinical Care

Short-Course Combo Therapy for Latent TB Equivalent to Longer Monotherapy


A 3-month combination treatment regimen (isoniazid plus rifapentine) for latent tuberculosis is as effective as the standard 9-month isoniazid regimen, according to an international study in the New England Journal of Medicine.

Some 7700 patients with latent TB and at high risk for progression were recruited, primarily in the United States and Canada. They underwent randomization either to 9 months of self-administered daily isoniazid or to 3 months of combination therapy, administered weekly under direct supervision. By follow-up at 3 years, confirmed TB had developed in 0.2% of the combination-therapy group and 0.4% of those taking isoniazid only, showing that short-course combination therapy was noninferior to standard therapy. Patients taking combination therapy were more likely to discontinue treatment (5% vs. 4%).

Hepatotoxicity was more common in the isoniazid-only group, but hypersensitivity reactions were more common with combination therapy.

Source:NEJM